nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—RYR3—diaphragm—esophageal cancer	0.271	0.596	CbGeAlD
Dantrolene—RYR1—larynx—esophageal cancer	0.103	0.226	CbGeAlD
Dantrolene—RYR3—smooth muscle tissue—esophageal cancer	0.0249	0.0548	CbGeAlD
Dantrolene—RYR3—digestive system—esophageal cancer	0.0197	0.0432	CbGeAlD
Dantrolene—RYR1—smooth muscle tissue—esophageal cancer	0.0179	0.0393	CbGeAlD
Dantrolene—RYR3—lung—esophageal cancer	0.0164	0.0361	CbGeAlD
Dantrolene—Infusion site pain—Capecitabine—esophageal cancer	0.0148	0.0565	CcSEcCtD
Dantrolene—Extravasation—Carboplatin—esophageal cancer	0.0129	0.0492	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—GAPDH—esophageal cancer	0.0114	0.0403	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ATP1B2—esophageal cancer	0.0108	0.0383	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—ATP1B2—esophageal cancer	0.0101	0.0359	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—FKBP1A—esophageal cancer	0.01	0.0355	CbGpPWpGaD
Dantrolene—Phlebitis—Carboplatin—esophageal cancer	0.00949	0.0362	CcSEcCtD
Dantrolene—RYR3—Ion channel transport—ATP4A—esophageal cancer	0.0088	0.0311	CbGpPWpGaD
Dantrolene—Speech impairment NOS—Methotrexate—esophageal cancer	0.0083	0.0316	CcSEcCtD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ATP1B2—esophageal cancer	0.008	0.0283	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—ATP1B2—esophageal cancer	0.00748	0.0264	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—FKBP1A—esophageal cancer	0.0074	0.0262	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—GSTO1—esophageal cancer	0.0072	0.0255	CbGpPWpGaD
Dantrolene—Chromaturia—Capecitabine—esophageal cancer	0.00682	0.026	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—PDE4D—esophageal cancer	0.00659	0.0233	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—ATP4A—esophageal cancer	0.00649	0.0229	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GNG7—esophageal cancer	0.00647	0.0229	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—SFN—esophageal cancer	0.00642	0.0227	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—GNG7—esophageal cancer	0.00627	0.0222	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—SFN—esophageal cancer	0.00622	0.022	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—ACTB—esophageal cancer	0.00565	0.02	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—GSTO1—esophageal cancer	0.00531	0.0188	CbGpPWpGaD
Dantrolene—Lymphoma—Methotrexate—esophageal cancer	0.00519	0.0198	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—CALR—esophageal cancer	0.00511	0.0181	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—PDE4D—esophageal cancer	0.00486	0.0172	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GNG7—esophageal cancer	0.00477	0.0169	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—SFN—esophageal cancer	0.00473	0.0167	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—GNG7—esophageal cancer	0.00462	0.0163	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—SFN—esophageal cancer	0.00459	0.0162	CbGpPWpGaD
Dantrolene—Hepatotoxicity—Cisplatin—esophageal cancer	0.00428	0.0163	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—CASP8—esophageal cancer	0.00422	0.0149	CbGpPWpGaD
Dantrolene—Necrosis—Cisplatin—esophageal cancer	0.00421	0.016	CcSEcCtD
Dantrolene—Pericarditis—Methotrexate—esophageal cancer	0.00419	0.016	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—ACTB—esophageal cancer	0.00417	0.0147	CbGpPWpGaD
Dantrolene—Extravasation—Cisplatin—esophageal cancer	0.00379	0.0144	CcSEcCtD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00378	0.0134	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—CALR—esophageal cancer	0.00377	0.0133	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00376	0.0133	CbGpPWpGaD
Dantrolene—Intestinal obstruction—Capecitabine—esophageal cancer	0.00357	0.0136	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00353	0.0125	CbGpPWpGaD
Dantrolene—Pain—Carboplatin—esophageal cancer	0.00344	0.0131	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00335	0.0118	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00319	0.0113	CbGpPWpGaD
Dantrolene—Pleural effusion—Capecitabine—esophageal cancer	0.00318	0.0121	CcSEcCtD
Dantrolene—Body temperature increased—Carboplatin—esophageal cancer	0.00318	0.0121	CcSEcCtD
Dantrolene—Hepatotoxicity—Capecitabine—esophageal cancer	0.00315	0.012	CcSEcCtD
Dantrolene—Coagulopathy—Capecitabine—esophageal cancer	0.00313	0.0119	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00306	0.0108	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00306	0.0108	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00299	0.0106	CbGpPWpGaD
Dantrolene—Dysphonia—Capecitabine—esophageal cancer	0.00296	0.0113	CcSEcCtD
Dantrolene—Eruption—Methotrexate—esophageal cancer	0.00295	0.0112	CcSEcCtD
Dantrolene—Phlebitis—Cisplatin—esophageal cancer	0.00278	0.0106	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00277	0.00979	CbGpPWpGaD
Dantrolene—Lacrimation increased—Capecitabine—esophageal cancer	0.00264	0.0101	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00263	0.00929	CbGpPWpGaD
Dantrolene—Nocturia—Capecitabine—esophageal cancer	0.00262	0.01	CcSEcCtD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00262	0.00926	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.0026	0.0092	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00247	0.00872	CbGpPWpGaD
Dantrolene—CYP3A4—digestive system—esophageal cancer	0.00245	0.00539	CbGeAlD
Dantrolene—Injection site reaction—Capecitabine—esophageal cancer	0.00242	0.00922	CcSEcCtD
Dantrolene—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00242	0.00854	CbGpPWpGaD
Dantrolene—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.0024	0.00914	CcSEcCtD
Dantrolene—Pleural effusion—Methotrexate—esophageal cancer	0.00237	0.00902	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00235	0.00832	CbGpPWpGaD
Dantrolene—Urinary incontinence—Capecitabine—esophageal cancer	0.00235	0.00896	CcSEcCtD
Dantrolene—Hepatotoxicity—Methotrexate—esophageal cancer	0.00235	0.00894	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00232	0.0082	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00232	0.0082	CbGpPWpGaD
Dantrolene—Necrosis—Methotrexate—esophageal cancer	0.00231	0.0088	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00226	0.00798	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00226	0.00798	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00222	0.00783	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—NOS3—esophageal cancer	0.00219	0.00775	CbGpPWpGaD
Dantrolene—Speech disorder—Methotrexate—esophageal cancer	0.00211	0.00803	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00211	0.00744	CbGpPWpGaD
Dantrolene—Extravasation—Methotrexate—esophageal cancer	0.00208	0.00792	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00207	0.00731	CbGpPWpGaD
Dantrolene—Phlebitis—Capecitabine—esophageal cancer	0.00205	0.00782	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TP53—esophageal cancer	0.00205	0.00724	CbGpPWpGaD
Dantrolene—Thrombophlebitis—Capecitabine—esophageal cancer	0.00204	0.00778	CcSEcCtD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00201	0.00709	CbGpPWpGaD
Dantrolene—Swelling—Capecitabine—esophageal cancer	0.002	0.00763	CcSEcCtD
Dantrolene—Hepatic failure—Capecitabine—esophageal cancer	0.00197	0.00749	CcSEcCtD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00185	0.00652	CbGpPWpGaD
Dantrolene—Respiratory failure—Methotrexate—esophageal cancer	0.00185	0.00703	CcSEcCtD
Dantrolene—Renal failure—Cisplatin—esophageal cancer	0.00182	0.00692	CcSEcCtD
Dantrolene—Cardiac failure—Capecitabine—esophageal cancer	0.00181	0.0069	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00177	0.00673	CcSEcCtD
Dantrolene—Pain in extremity—Capecitabine—esophageal cancer	0.00177	0.00673	CcSEcCtD
Dantrolene—Diplopia—Capecitabine—esophageal cancer	0.00177	0.00673	CcSEcCtD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00174	0.00613	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00171	0.00605	CbGpPWpGaD
Dantrolene—Aplastic anaemia—Methotrexate—esophageal cancer	0.0017	0.00648	CcSEcCtD
Dantrolene—Urinary retention—Capecitabine—esophageal cancer	0.00168	0.0064	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—NOS3—esophageal cancer	0.00162	0.00571	CbGpPWpGaD
Dantrolene—Pulmonary oedema—Methotrexate—esophageal cancer	0.00161	0.00615	CcSEcCtD
Dantrolene—Visual impairment—Cisplatin—esophageal cancer	0.0016	0.00609	CcSEcCtD
Dantrolene—Muscular weakness—Capecitabine—esophageal cancer	0.00156	0.00594	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00155	0.00549	CbGpPWpGaD
Dantrolene—Flushing—Cisplatin—esophageal cancer	0.00154	0.00587	CcSEcCtD
Dantrolene—Dysphagia—Capecitabine—esophageal cancer	0.00153	0.00582	CcSEcCtD
Dantrolene—Thrombophlebitis—Methotrexate—esophageal cancer	0.00152	0.00579	CcSEcCtD
Dantrolene—Hepatic failure—Methotrexate—esophageal cancer	0.00146	0.00558	CcSEcCtD
Dantrolene—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00145	0.00513	CbGpPWpGaD
Dantrolene—Erythema—Cisplatin—esophageal cancer	0.00144	0.0055	CcSEcCtD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.0014	0.00493	CbGpPWpGaD
Dantrolene—Visual disturbance—Methotrexate—esophageal cancer	0.00139	0.00529	CcSEcCtD
Dantrolene—Vision blurred—Cisplatin—esophageal cancer	0.00136	0.00518	CcSEcCtD
Dantrolene—Depression—Capecitabine—esophageal cancer	0.00136	0.00517	CcSEcCtD
Dantrolene—Ill-defined disorder—Cisplatin—esophageal cancer	0.00134	0.0051	CcSEcCtD
Dantrolene—Renal failure—Capecitabine—esophageal cancer	0.00134	0.0051	CcSEcCtD
Dantrolene—Anaemia—Cisplatin—esophageal cancer	0.00133	0.00508	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00133	0.00471	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00133	0.00471	CbGpPWpGaD
Dantrolene—Malaise—Cisplatin—esophageal cancer	0.0013	0.00496	CcSEcCtD
Dantrolene—Haematuria—Capecitabine—esophageal cancer	0.0013	0.00495	CcSEcCtD
Dantrolene—Leukopenia—Cisplatin—esophageal cancer	0.00129	0.00492	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00128	0.00453	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00127	0.0045	CbGpPWpGaD
Dantrolene—Convulsion—Cisplatin—esophageal cancer	0.00125	0.00477	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00125	0.00441	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00123	0.00435	CbGpPWpGaD
Dantrolene—Myalgia—Cisplatin—esophageal cancer	0.00123	0.00468	CcSEcCtD
Dantrolene—Haemoglobin—Capecitabine—esophageal cancer	0.00123	0.00468	CcSEcCtD
Dantrolene—Hepatitis—Capecitabine—esophageal cancer	0.00122	0.00466	CcSEcCtD
Dantrolene—Haemorrhage—Capecitabine—esophageal cancer	0.00122	0.00466	CcSEcCtD
Dantrolene—Discomfort—Cisplatin—esophageal cancer	0.00121	0.00463	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00119	0.0042	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Cisplatin—esophageal cancer	0.00118	0.00449	CcSEcCtD
Dantrolene—Visual impairment—Capecitabine—esophageal cancer	0.00118	0.00449	CcSEcCtD
Dantrolene—Thrombocytopenia—Cisplatin—esophageal cancer	0.00115	0.0044	CcSEcCtD
Dantrolene—Tachycardia—Cisplatin—esophageal cancer	0.00115	0.00438	CcSEcCtD
Dantrolene—Hyperhidrosis—Cisplatin—esophageal cancer	0.00114	0.00434	CcSEcCtD
Dantrolene—Flushing—Capecitabine—esophageal cancer	0.00113	0.00432	CcSEcCtD
Dantrolene—Eosinophilia—Methotrexate—esophageal cancer	0.00113	0.00429	CcSEcCtD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00113	0.00398	CbGpPWpGaD
Dantrolene—Anorexia—Cisplatin—esophageal cancer	0.00112	0.00428	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.0011	0.00388	CbGpPWpGaD
Dantrolene—Chills—Capecitabine—esophageal cancer	0.0011	0.00418	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00107	0.00409	CcSEcCtD
Dantrolene—Erythema—Capecitabine—esophageal cancer	0.00106	0.00406	CcSEcCtD
Dantrolene—Dysgeusia—Capecitabine—esophageal cancer	0.00104	0.00397	CcSEcCtD
Dantrolene—Back pain—Capecitabine—esophageal cancer	0.00103	0.00392	CcSEcCtD
Dantrolene—Decreased appetite—Cisplatin—esophageal cancer	0.00102	0.0039	CcSEcCtD
Dantrolene—Drowsiness—Methotrexate—esophageal cancer	0.00101	0.00386	CcSEcCtD
Dantrolene—Depression—Methotrexate—esophageal cancer	0.00101	0.00385	CcSEcCtD
Dantrolene—Pain—Cisplatin—esophageal cancer	0.00101	0.00384	CcSEcCtD
Dantrolene—Vision blurred—Capecitabine—esophageal cancer	0.001	0.00382	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000997	0.00352	CbGpPWpGaD
Dantrolene—Renal failure—Methotrexate—esophageal cancer	0.000997	0.0038	CcSEcCtD
Dantrolene—Ill-defined disorder—Capecitabine—esophageal cancer	0.000987	0.00376	CcSEcCtD
Dantrolene—Anaemia—Capecitabine—esophageal cancer	0.000984	0.00375	CcSEcCtD
Dantrolene—Sweating—Methotrexate—esophageal cancer	0.000972	0.0037	CcSEcCtD
Dantrolene—Feeling abnormal—Cisplatin—esophageal cancer	0.000971	0.0037	CcSEcCtD
Dantrolene—Haematuria—Methotrexate—esophageal cancer	0.000967	0.00368	CcSEcCtD
Dantrolene—Malaise—Capecitabine—esophageal cancer	0.00096	0.00366	CcSEcCtD
Dantrolene—Leukopenia—Capecitabine—esophageal cancer	0.000953	0.00363	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000946	0.00334	CbGpPWpGaD
Dantrolene—Body temperature increased—Cisplatin—esophageal cancer	0.000931	0.00355	CcSEcCtD
Dantrolene—Hypertension—Capecitabine—esophageal cancer	0.000919	0.0035	CcSEcCtD
Dantrolene—Haemoglobin—Methotrexate—esophageal cancer	0.000915	0.00349	CcSEcCtD
Dantrolene—Haemorrhage—Methotrexate—esophageal cancer	0.00091	0.00347	CcSEcCtD
Dantrolene—Hepatitis—Methotrexate—esophageal cancer	0.00091	0.00347	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000908	0.00321	CbGpPWpGaD
Dantrolene—Myalgia—Capecitabine—esophageal cancer	0.000906	0.00345	CcSEcCtD
Dantrolene—Discomfort—Capecitabine—esophageal cancer	0.000895	0.00341	CcSEcCtD
Dantrolene—Dry mouth—Capecitabine—esophageal cancer	0.000886	0.00338	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—esophageal cancer	0.000877	0.00334	CcSEcCtD
Dantrolene—Confusional state—Capecitabine—esophageal cancer	0.000876	0.00334	CcSEcCtD
Dantrolene—Hypersensitivity—Cisplatin—esophageal cancer	0.000868	0.00331	CcSEcCtD
Dantrolene—Thrombocytopenia—Capecitabine—esophageal cancer	0.00085	0.00324	CcSEcCtD
Dantrolene—Tachycardia—Capecitabine—esophageal cancer	0.000848	0.00323	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000846	0.00299	CbGpPWpGaD
Dantrolene—Asthenia—Cisplatin—esophageal cancer	0.000845	0.00322	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000841	0.00297	CbGpPWpGaD
Dantrolene—Hyperhidrosis—Capecitabine—esophageal cancer	0.00084	0.0032	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000835	0.00295	CbGpPWpGaD
Dantrolene—Anorexia—Capecitabine—esophageal cancer	0.000828	0.00315	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000823	0.00291	CbGpPWpGaD
Dantrolene—Chills—Methotrexate—esophageal cancer	0.000817	0.00311	CcSEcCtD
Dantrolene—Diarrhoea—Cisplatin—esophageal cancer	0.000806	0.00307	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000793	0.0028	CbGpPWpGaD
Dantrolene—Erythema—Methotrexate—esophageal cancer	0.000792	0.00302	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000791	0.00302	CcSEcCtD
Dantrolene—Insomnia—Capecitabine—esophageal cancer	0.000786	0.00299	CcSEcCtD
Dantrolene—Dysgeusia—Methotrexate—esophageal cancer	0.000776	0.00296	CcSEcCtD
Dantrolene—Back pain—Methotrexate—esophageal cancer	0.000766	0.00292	CcSEcCtD
Dantrolene—Dyspepsia—Capecitabine—esophageal cancer	0.000765	0.00291	CcSEcCtD
Dantrolene—Decreased appetite—Capecitabine—esophageal cancer	0.000755	0.00288	CcSEcCtD
Dantrolene—Vomiting—Cisplatin—esophageal cancer	0.000749	0.00285	CcSEcCtD
Dantrolene—Fatigue—Capecitabine—esophageal cancer	0.000749	0.00285	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—esophageal cancer	0.000747	0.00285	CcSEcCtD
Dantrolene—Rash—Cisplatin—esophageal cancer	0.000743	0.00283	CcSEcCtD
Dantrolene—Constipation—Capecitabine—esophageal cancer	0.000743	0.00283	CcSEcCtD
Dantrolene—Pain—Capecitabine—esophageal cancer	0.000743	0.00283	CcSEcCtD
Dantrolene—Dermatitis—Cisplatin—esophageal cancer	0.000742	0.00283	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000738	0.00261	CbGpPWpGaD
Dantrolene—Ill-defined disorder—Methotrexate—esophageal cancer	0.000735	0.0028	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—esophageal cancer	0.000732	0.00279	CcSEcCtD
Dantrolene—Feeling abnormal—Capecitabine—esophageal cancer	0.000716	0.00273	CcSEcCtD
Dantrolene—Malaise—Methotrexate—esophageal cancer	0.000714	0.00272	CcSEcCtD
Dantrolene—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00071	0.00271	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—esophageal cancer	0.000709	0.0027	CcSEcCtD
Dantrolene—Nausea—Cisplatin—esophageal cancer	0.0007	0.00267	CcSEcCtD
Dantrolene—Urticaria—Capecitabine—esophageal cancer	0.00069	0.00263	CcSEcCtD
Dantrolene—Abdominal pain—Capecitabine—esophageal cancer	0.000687	0.00262	CcSEcCtD
Dantrolene—Body temperature increased—Capecitabine—esophageal cancer	0.000687	0.00262	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—esophageal cancer	0.000686	0.00262	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000686	0.00242	CbGpPWpGaD
Dantrolene—Myalgia—Methotrexate—esophageal cancer	0.000675	0.00257	CcSEcCtD
Dantrolene—Discomfort—Methotrexate—esophageal cancer	0.000666	0.00254	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000662	0.00234	CbGpPWpGaD
Dantrolene—Confusional state—Methotrexate—esophageal cancer	0.000652	0.00248	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—esophageal cancer	0.000647	0.00246	CcSEcCtD
Dantrolene—Hypersensitivity—Capecitabine—esophageal cancer	0.00064	0.00244	CcSEcCtD
Dantrolene—Thrombocytopenia—Methotrexate—esophageal cancer	0.000633	0.00241	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00063	0.00223	CbGpPWpGaD
Dantrolene—Hyperhidrosis—Methotrexate—esophageal cancer	0.000625	0.00238	CcSEcCtD
Dantrolene—Asthenia—Capecitabine—esophageal cancer	0.000623	0.00237	CcSEcCtD
Dantrolene—Anorexia—Methotrexate—esophageal cancer	0.000616	0.00235	CcSEcCtD
Dantrolene—Pruritus—Capecitabine—esophageal cancer	0.000615	0.00234	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000607	0.00214	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000603	0.00213	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000601	0.00212	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000595	0.0021	CbGpPWpGaD
Dantrolene—Diarrhoea—Capecitabine—esophageal cancer	0.000594	0.00226	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000589	0.00224	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—esophageal cancer	0.000585	0.00223	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—esophageal cancer	0.000575	0.00219	CcSEcCtD
Dantrolene—Dizziness—Capecitabine—esophageal cancer	0.000574	0.00219	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—esophageal cancer	0.000569	0.00217	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000565	0.002	CbGpPWpGaD
Dantrolene—Decreased appetite—Methotrexate—esophageal cancer	0.000562	0.00214	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—esophageal cancer	0.000557	0.00212	CcSEcCtD
Dantrolene—Pain—Methotrexate—esophageal cancer	0.000553	0.00211	CcSEcCtD
Dantrolene—Vomiting—Capecitabine—esophageal cancer	0.000552	0.0021	CcSEcCtD
Dantrolene—Rash—Capecitabine—esophageal cancer	0.000548	0.00209	CcSEcCtD
Dantrolene—Dermatitis—Capecitabine—esophageal cancer	0.000547	0.00208	CcSEcCtD
Dantrolene—Headache—Capecitabine—esophageal cancer	0.000544	0.00207	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—esophageal cancer	0.000533	0.00203	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000529	0.00201	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00052	0.00184	CbGpPWpGaD
Dantrolene—Nausea—Capecitabine—esophageal cancer	0.000516	0.00197	CcSEcCtD
Dantrolene—Urticaria—Methotrexate—esophageal cancer	0.000514	0.00196	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—esophageal cancer	0.000511	0.00195	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—esophageal cancer	0.000511	0.00195	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000489	0.00173	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000486	0.00172	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000479	0.00169	CbGpPWpGaD
Dantrolene—Hypersensitivity—Methotrexate—esophageal cancer	0.000476	0.00182	CcSEcCtD
Dantrolene—Asthenia—Methotrexate—esophageal cancer	0.000464	0.00177	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000463	0.00164	CbGpPWpGaD
Dantrolene—Pruritus—Methotrexate—esophageal cancer	0.000457	0.00174	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000457	0.00161	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000451	0.00159	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000447	0.00158	CbGpPWpGaD
Dantrolene—Diarrhoea—Methotrexate—esophageal cancer	0.000442	0.00169	CcSEcCtD
Dantrolene—Dizziness—Methotrexate—esophageal cancer	0.000428	0.00163	CcSEcCtD
Dantrolene—Vomiting—Methotrexate—esophageal cancer	0.000411	0.00157	CcSEcCtD
Dantrolene—Rash—Methotrexate—esophageal cancer	0.000408	0.00155	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—esophageal cancer	0.000407	0.00155	CcSEcCtD
Dantrolene—Headache—Methotrexate—esophageal cancer	0.000405	0.00154	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000394	0.00139	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000392	0.00138	CbGpPWpGaD
Dantrolene—Nausea—Methotrexate—esophageal cancer	0.000384	0.00146	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00037	0.00131	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000364	0.00129	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000359	0.00127	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000339	0.0012	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000334	0.00118	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000276	0.000976	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000263	0.000928	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00026	0.000917	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000246	0.00087	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000209	0.000739	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000206	0.000729	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000197	0.000695	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000194	0.000686	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000106	0.000374	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000106	0.000374	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CA1—esophageal cancer	8.99e-05	0.000318	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC10A2—esophageal cancer	8.99e-05	0.000318	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CA2—esophageal cancer	8.22e-05	0.000291	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ADH7—esophageal cancer	7.64e-05	0.00027	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLCE1—esophageal cancer	7.64e-05	0.00027	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ADH1B—esophageal cancer	6.7e-05	0.000237	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TYMP—esophageal cancer	6.4e-05	0.000226	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.23e-05	0.00022	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.07e-05	0.000215	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TPI1—esophageal cancer	5.79e-05	0.000205	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTO1—esophageal cancer	5.79e-05	0.000205	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.55e-05	0.000196	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.34e-05	0.000189	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.3e-05	0.000187	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GNG7—esophageal cancer	5.04e-05	0.000178	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.72e-05	0.000167	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.49e-05	0.000159	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.44e-05	0.000157	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ENO1—esophageal cancer	4.21e-05	0.000149	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.21e-05	0.000149	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PSME2—esophageal cancer	4.15e-05	0.000147	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PSME1—esophageal cancer	4.15e-05	0.000147	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.58e-05	0.000126	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.36e-05	0.000119	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.07e-05	0.000108	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.95e-05	0.000104	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.97e-05	6.96e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NOS3—esophageal cancer	1.76e-05	6.23e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.61e-05	5.7e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—EP300—esophageal cancer	1.34e-05	4.74e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CA—esophageal cancer	9.92e-06	3.51e-05	CbGpPWpGaD
